Medtech company Osteopore (ASX: OSX) will soon have it’s 3D-printed bone regeneration products in the view of major international medical markets through a new collaboration with one of the world’s largest medical companies.

The cross-promotion agreement is with Terumo Blood and Cell Technologies which is wholly owned by Japanese medical conglomerate Terumo (TYO: 4543) which generates more than $8 billion annual revenue.

Between the two parties, respective sales teams will be educated in each others products where Terumo Blood and Cell Technologies’ Autologous Biologics (TAB) technology extracts concentrated bone marrow for bone regeneration while Osteopore’s provides biomimetic scaffolding to guide the bone tissue formation.

Targeted applications of the cross-promoted products include Neurosurgery, Orthopaedics and Reconstructive surgeries and will draw upon Terumo’s extensive network of blood centres, hospitals, therapeutic clinics, researchers, and private medical practices in the Asia-Pacific region.

Further commercial opportunities will be explored by the partnership which would commence with investigator-initiated studies.

For the 12 months ending 31 December 2020, Osteopore reported $1.5 million in sales which represented a 36% increase from the previous year. This was generated primarily through Osteopore’s 3D-printed scaffold tissue that naturally dissolves over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.